DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Yes. Switching from Ozempic (semaglutide) to Mounjaro (tirzepatide) is common and clinically supported for type 2 diabetes patients seeking better A1C reduction.
Switching from Ozempic to Mounjaro is straightforward for type 2 diabetes patients. Your clinician will typically wait one week after your last Ozempic dose, then start Mounjaro at the 2.5mg starter dose, even if you were on a higher Ozempic dose. The molecules work differently — semaglutide is a GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist — so you titrate Mounjaro from the beginning regardless of Ozempic dose history. SURPASS-2 head-to-head data shows Mounjaro reduces A1C by ~2.3% vs Ozempic ~1.9%. For weight loss switching, switch to Zepbound (same tirzepatide, weight-loss FDA indication) to avoid off-label PA denials.
Editorial answer reviewed by a board-certified clinician. Not medical advice. Coordinate treatment decisions with your prescriber.